| Domain | Established finding | Evidence/model | Key quantitative or variant detail | Caveat |
|---|---|---|---|---|
| Phenotype and epidemiology | UV-sensitive syndrome (UVSS) is a mild, usually isolated cutaneous photosensitivity disorder characterized by exaggerated sunburn, freckling or pigmentary change, telangiectasia, and xerosis on sun-exposed skin; classic Cockayne neurologic, developmental, and systemic abnormalities are absent. | Aggregated case literature and reviews; DOI: [10.1016/j.mrfmmm.2014.11.003](https://doi.org/10.1016/j.mrfmmm.2014.11.003) and [10.47391/JPMA.03-476](https://doi.org/10.47391/JPMA.03-476) (pqac-00000001, pqac-00000002, pqac-00000007) | A 2021 review counted 18 patients from nine families of Japanese, French, Israeli, Iranian, and Pakistani ancestry. | Extreme rarity and likely underdiagnosis preclude reliable incidence, prevalence, penetrance, sex-ratio, or phenotype-frequency estimates. The reported 1:100,000 prevalence lacks population surveillance support. No tumor predisposition is established, but limited cohorts cannot prove zero risk. |
| ERCC6/CSB | Biallelic **ERCC6** loss can cause UVSS1 rather than Cockayne syndrome, showing that genotype alone does not fully explain the clinical difference between these TC-NER disorders. | Human patients, fibroblast complementation, and molecular studies; DOI: [10.1073/pnas.0404587101](https://doi.org/10.1073/pnas.0404587101) and [10.1038/ng.2229](https://doi.org/10.1038/ng.2229) (pqac-00000004, pqac-00000005) | Two reported patients were homozygous for **ERCC6 c.229C>T (p.Arg77Ter)**, producing severe N-terminal truncation or absence of CSB. | Some secondary sources give inconsistent cDNA numbering for p.Arg77Ter; HGVS should be validated against the specified transcript. ERCC6 variants more commonly cause Cockayne syndrome. |
| ERCC8/CSA | Biallelic **ERCC8** variants cause UVSS2; CSA is a substrate-receptor component of the CRL4CSA ubiquitin-ligase complex involved in TC-NER assembly. | Human cases, segregation, and patient-cell studies; DOI: [10.1038/ng.2229](https://doi.org/10.1038/ng.2229) and [10.2340/00015555-3032](https://doi.org/10.2340/00015555-3032) (pqac-00000005, pqac-00000006) | Reported alleles include homozygous **c.1083G>T (p.Trp361Cys)** and **c.582G>T** plus **c.769G>A (p.Gly257Arg)** in a Chinese case; c.769G>A was reported below 0.01% in a Chinese dataset. | ERCC8 also causes Cockayne syndrome type A, so variant-specific functional and clinical context is essential. Current ClinVar classifications and gnomAD frequencies require independent verification. |
| UVSSA | Biallelic loss-of-function variants in **UVSSA** cause UVSS3 or UVSS-A and impair recovery of transcription after UV by disrupting TC-NER recruitment or stabilization. | Whole-exome sequencing, patient fibroblasts, complementation, and functional assays; DOI: [10.1038/ng.2229](https://doi.org/10.1038/ng.2229) (pqac-00000003, pqac-00000004) | Reported variants include **c.367A>T (p.Lys123Ter)**, **c.94T>C (p.Cys32Arg)**, **c.87delG (p.Ile31PhefsTer9)**, and **c.1040G>A**, reported as a codon-347 truncating allele. | Secondary sources inconsistently label c.1040G>A as p.Trp347Ter or p.Tyr347Ter; transcript and reference-sequence validation is mandatory. Population frequencies and ACMG classifications were not uniformly reported. |
| Cellular diagnostics | UVSS cells show increased UV cytotoxicity and defective recovery of RNA synthesis after UV, while global-genome photoproduct repair or unscheduled DNA synthesis is relatively preserved, indicating selective TC-NER deficiency. | Cultured patient fibroblasts assessed by post-UV survival, recovery of RNA synthesis, unscheduled DNA synthesis, and complementation (pqac-00000001, pqac-00000004, pqac-00000006) | Characteristic qualitative pattern: low UV survival plus abnormal recovery of RNA synthesis with near-normal global repair. | These are specialized assays without universal clinical cutoffs. Molecular confirmation of biallelic pathogenic variants is preferred. |
| Canonical TC-NER | A transcription-blocking UV photoproduct stalls RNA polymerase II; CSB binds first, recruits CRL4CSA or CSA, and facilitates ELOF1-dependent UVSSA positioning. UVSSA helps inactivate stalled polymerase and recruit TFIIH; XPA, RPA, XPG, and XPF-ERCC1 then support verification, dual incision, repair synthesis, and ligation. | Patient cells, isogenic knockout cells, biochemistry, and structural biology; DOI: [10.1038/ng.2229](https://doi.org/10.1038/ng.2229) and [10.1101/707216](https://doi.org/10.1101/707216) (pqac-00000004, pqac-00000007, pqac-00000014) | UVSSA contains an N-terminal CSA-interacting region and a C-terminal TFIIH-interacting region around amino acids 400–500. | The pathway integrates multiple experimental systems. Some early models of RNAPII backtracking and degradation have been refined by later structural work. |
| 2024 structural advance | Cryo-EM and functional work showed that ELOF1 positions UVSSA and CRL4CSA on arrested Pol II, activating Pol II ubiquitylation. A TFIIS-like UVSSA element enters the Pol II pore and prevents TFIIS-mediated transcription reactivation, while other UVSSA regions promote TFIIH recruitment. | Structural, biochemical, immunoprecipitation, complementation, and nascent-RNA assays; February 2024; DOI: [10.1038/s41594-023-01207-0](https://doi.org/10.1038/s41594-023-01207-0) (pqac-00000009, pqac-00000010) | UVSSA zinc-finger and K414-site mutants could preserve Pol II ubiquitylation while reducing TFIIH interaction, separating polymerase inactivation from repair recruitment. | Primarily mechanistic work in reconstituted complexes and cultured cells, not a clinical or natural-history study; direct genotype-phenotype prediction remains uncertain. |
| 2024 interstrand-crosslink finding | UVSSA also facilitates transcription-coupled repair of DNA interstrand crosslinks: loss sensitized human cells to crosslinking agents, delayed repair, and impaired a single-ICL reporter; rescue required intact UVSSA-TFIIH interaction. | Human HAP1 and MCF10A cells, clonogenic assays, reporter repair, chromatin fractionation, co-immunoprecipitation, and proteomics; DOI: [10.1101/2023.05.10.538304](https://doi.org/10.1101/2023.05.10.538304) (pqac-00000011, pqac-00000012, pqac-00000013) | UVSSA loss reduced reporter ICL-repair efficiency by approximately 50%; **F408A/V411A**, defective in TFIIH binding, failed to rescue. | Initially reported as a preprint; relevance to untreated UVSS patients and clinical crosslinker toxicity is unproven. |
| Management and trials | Care is preventive and supportive: rigorous UV avoidance, broad-spectrum sunscreen, UV-protective clothing and gloves, sunglasses, environmental UV controls, dermatologic surveillance, emollients, genetic counseling, and cascade testing. | Expert-review recommendations and photoprotection practice; DOI: [10.47391/JPMA.03-476](https://doi.org/10.47391/JPMA.03-476) (pqac-00000002, pqac-00000008) | No disease-modifying drug, gene therapy, validated pharmacogenomic strategy, response rate, or UVSS-specific interventional trial was identified. | Recommendations are extrapolated from pathophysiology and related photodermatoses rather than controlled UVSS trials. Topical corticosteroids should be used only for clinically indicated inflammation. |


*Table: Compact evidence table summarizing the phenotype, causal genes and variants, diagnostic cellular signature, TC-NER mechanism, 2024 mechanistic advances, and present management of UV-sensitive syndrome. Major evidence limitations and nomenclature issues are identified explicitly.*